NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis $10.20 -0.01 (-0.05%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About iTeos Therapeutics Stock (NASDAQ:ITOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iTeos Therapeutics alerts:Sign Up Key Stats Today's Range$10.18▼$10.2250-Day Range$9.95▼$10.3552-Week Range$4.80▼$18.01Volume383,619 shsAverage Volume936,019 shsMarket Capitalization$450.72 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingHold Company Overview iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA. Read More iTeos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreITOS MarketRank™: iTeos Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 601st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingiTeos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageiTeos Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about iTeos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.49) to ($4.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.83% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.83% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for iTeos Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for ITOS on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,805,412.00 in company stock.Percentage Held by Insiders14.20% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iTeos Therapeutics' insider trading history. Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Stock News HeadlinesSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of ShareholdersAugust 20 at 11:05 AM | prnewswire.comITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOSAugust 19 at 9:05 PM | globenewswire.comI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning about a dangerous flaw in America’s financial system for 15 years, he believed Trump might fix it. Instead, he says the problem has only grown worse. In his new emergency broadcast, Breaking Point, Porter reveals why this flaw may now be irreversible—and how it could gut retirement accounts, trigger mass wealth destruction, and blindside hard-working investors.August 22 at 2:00 AM | Porter & Company (Ad)Q3 EPS Estimates for iTeos Therapeutics Lifted by WedbushAugust 11, 2025 | americanbankingnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of ShareholdersJuly 21, 2025 | globenewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.July 21, 2025 | prnewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)July 21, 2025 | globenewswire.comITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to ShareholdersJuly 21, 2025 | tmcnet.comSee More Headlines ITOS Stock Analysis - Frequently Asked Questions How have ITOS shares performed this year? iTeos Therapeutics' stock was trading at $7.68 on January 1st, 2025. Since then, ITOS shares have increased by 32.7% and is now trading at $10.1950. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by $0.39. When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? iTeos Therapeutics' top institutional shareholders include EcoR1 Capital LLC (24.18%), Geode Capital Management LLC (1.84%), Orbimed Advisors LLC (1.58%) and Marshall Wace LLP (1.38%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2018 LP Mpm, Boxer Capital, Llc, Michel Detheux, Matthew Gall and David Hallal. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/06/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITOS CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for iTeos Therapeutics$15.50 High Price Target$46.00 Low Price Target$8.00 Potential Upside/Downside+52.0%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.41 million Net MarginsN/A Pretax Margin-336.72% Return on Equity-33.26% Return on Assets-28.16% Debt Debt-to-Equity RatioN/A Current Ratio7.53 Quick Ratio7.53 Sales & Book Value Annual Sales$35 million Price / Sales12.88 Cash FlowN/A Price / Cash FlowN/A Book Value$11.17 per share Price / Book0.91Miscellaneous Outstanding Shares44,210,000Free Float37,928,000Market Cap$450.94 million OptionableOptionable Beta1.49 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ITOS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.